vimarsana.com

Latest Breaking News On - Philippe drouet - Page 1 : vimarsana.com

Biotheryx to Present New Preclinical Data on Bifunctional Degraders for CDK4/6 and SOS1 at 2023 ASCO Annual Meeting

/PRNewswire/ Biotheryx, Inc., a biopharmaceutical company discovering and developing a portfolio of first-in-class protein degraders with a focus on.

United statesKyle begovichHannah majeskiPhilippe drouetPrnewswire biotheryx incAmerican society of clinical oncologyClinical oncologyAnnual meetingChief executive officerMeeting presentation detailsPrincipal scientistBreast cancerSenior scientistDevelopmental therapeuticsMolecularly targeted agentsTumor biology

Biotheryx Inks Collaboration Deal with Incyte - San Diego Business Journal

Biotheryx Inks Collaboration Deal with Incyte - San Diego Business Journal
sdbj.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sdbj.com Daily Mail and Mail on Sunday newspapers.

Philippe drouetDashyant dhanakDavid stirlingBiotheryx incSan diego basedSan digo

Incyte and Biotheryx collaborate to develop protein degraders for oncology targets

Incyte and Biotheryx collaborate to develop protein degraders for oncology targets
pmlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pmlive.com Daily Mail and Mail on Sunday newspapers.

Philippe drouetDashyant dhanakRobert garbaccioMerck co

Biotheryx Announces Research Collaboration and License Agreement with Incyte for Discovery of Targeted Protein Degraders for Novel Oncology Targets

/PRNewswire/ Biotheryx, Inc., a biopharmaceutical company discovering and developing a portfolio of first-in-class protein degraders with a focus on.

Dashyant dhanakPhilippe drouetResearch collaborationPrnewswire biotheryx incChief executive officerExecutive vice presidentChief scientific officer

Biotheryx Announces Appointment of Tracy Lawhon as Chief Development Officer

/PRNewswire/ Biotheryx, Inc., a clinical stage company discovering and developing a portfolio of innovative small molecule targeted protein degraders (TPDs).

Philippe drouetTracy lawhonIndiana universityAdastra pharmaceuticals incIndiana university school of lawPlough research instituteClinical operations at valo health incCabrellis pharmaceuticalsPrnewswire biotheryx incStrategic developmentChief development officerChief executive officerVice presidentClinical operationsValo health incAdastra pharmaceuticals

vimarsana © 2020. All Rights Reserved.